Provider Implicit Bias Impacts Pediatric Type 1 Diabetes Technology Recommendations in the United States: Findings from The Gatekeeper Study.


Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
09 2021
Historique:
pubmed: 17 4 2021
medline: 3 11 2021
entrez: 16 4 2021
Statut: ppublish

Résumé

Diabetes technology use is associated with favorable type 1 diabetes (T1D) outcomes. American youth with public insurance, a proxy for low socioeconomic status, use less diabetes technology than those with private insurance. We aimed to evaluate the role of insurance-mediated provider implicit bias, defined as the systematic discrimination of youth with public insurance, on diabetes technology recommendations for youth with T1D in the United States. Multi-disciplinary pediatric diabetes providers completed a bias assessment comprised of a clinical vignette and ranking exercises ( The majority of providers [44.1 ± 10.0 years old, 83% female, 79% non-Hispanic white, 49% physician, 12.2 ± 10.0 practice-years] demonstrated bias ( Provider bias to recommend technology based on insurance was common in our cohort and increased with years in practice. There are likely many reasons for this finding, including healthcare system drivers, yet as gatekeepers to diabetes technology, providers may be contributing to inequities in pediatric T1D in the United States.

Sections du résumé

BACKGROUND
Diabetes technology use is associated with favorable type 1 diabetes (T1D) outcomes. American youth with public insurance, a proxy for low socioeconomic status, use less diabetes technology than those with private insurance. We aimed to evaluate the role of insurance-mediated provider implicit bias, defined as the systematic discrimination of youth with public insurance, on diabetes technology recommendations for youth with T1D in the United States.
METHODS
Multi-disciplinary pediatric diabetes providers completed a bias assessment comprised of a clinical vignette and ranking exercises (
RESULTS
The majority of providers [44.1 ± 10.0 years old, 83% female, 79% non-Hispanic white, 49% physician, 12.2 ± 10.0 practice-years] demonstrated bias (
CONCLUSIONS
Provider bias to recommend technology based on insurance was common in our cohort and increased with years in practice. There are likely many reasons for this finding, including healthcare system drivers, yet as gatekeepers to diabetes technology, providers may be contributing to inequities in pediatric T1D in the United States.

Identifiants

pubmed: 33858206
doi: 10.1177/19322968211006476
pmc: PMC8442183
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1027-1033

Subventions

Organisme : NIDDK NIH HHS
ID : K12 DK122550
Pays : United States

Références

Diabetes Care. 2021 Jan;44(1):133-140
pubmed: 32938745
Diabetes Care. 2019 Jan;42(Suppl 1):S148-S164
pubmed: 30559239
BMC Med Ethics. 2017 Mar 1;18(1):19
pubmed: 28249596
Annu Rev Public Health. 2003;24:341-62
pubmed: 12471271
Pediatr Diabetes. 2016 Oct;17 Suppl 23:38-45
pubmed: 27417128
Diabetologia. 2016 Jan;59(1):87-91
pubmed: 26546085
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Diabetes Technol Ther. 2020 Mar;22(3):169-173
pubmed: 31596132
Acad Emerg Med. 2017 Aug;24(8):895-904
pubmed: 28472533
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Diabet Med. 2015 Nov;32(11):1445-52
pubmed: 26331364
J Adv Nurs. 2009 Sep;65(9):1937-45
pubmed: 19694857
J Diabetes Sci Technol. 2021 May;15(3):630-635
pubmed: 32172603
J Diabetes Sci Technol. 2018 Nov;12(6):1108-1115
pubmed: 29991281
Ann Intern Med. 2012 Sep 4;157(5):336-47
pubmed: 22777524
Am J Public Health. 2015 Dec;105(12):e60-76
pubmed: 26469668
Pediatrics. 2009 Dec;124(6):e1171-9
pubmed: 19884476
Diabetes Care. 2021 Jan;44(1):14-16
pubmed: 33444165
J Perinatol. 2019 Mar;39(3):354-358
pubmed: 30560947
Soc Sci Med. 2018 Feb;199:219-229
pubmed: 28532892
Lancet Diabetes Endocrinol. 2017 Jul;5(7):501-512
pubmed: 28533136
J Gen Intern Med. 2008 May;23(5):654-71
pubmed: 18301951
Diabetes Technol Ther. 2020 Sep;22(9):645-650
pubmed: 31905008
Pediatr Diabetes. 2015 Nov;16(7):546-53
pubmed: 25327782
Pediatr Diabetes. 2020 Nov;21(7):1301-1309
pubmed: 32681582
Pediatr Diabetes. 2018 Nov;19(7):1271-1275
pubmed: 29923262
Am J Public Health. 2012 May;102(5):988-95
pubmed: 22420817
Diabetes Technol Ther. 2019 Feb;21(2):66-72
pubmed: 30657336

Auteurs

Ananta Addala (A)

Department of Pediatrics, Division of Endocrinology, Stanford University, Stanford, CA, USA.

Sarah Hanes (S)

Department of Pediatrics, Division of Endocrinology, Stanford University, Stanford, CA, USA.

Diana Naranjo (D)

Department of Pediatrics, Division of Endocrinology, Stanford University, Stanford, CA, USA.
Stanford Diabetes Research Center, Stanford, CA, USA.

David M Maahs (DM)

Department of Pediatrics, Division of Endocrinology, Stanford University, Stanford, CA, USA.
Stanford Diabetes Research Center, Stanford, CA, USA.

Korey K Hood (KK)

Department of Pediatrics, Division of Endocrinology, Stanford University, Stanford, CA, USA.
Stanford Diabetes Research Center, Stanford, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH